


# Hereditary Cancer Portfolio Overview

## Setting the Standard in Genetic Testing

25 YEARS OF INNOVATION AND DISCOVERIES



• First to systematically use CRISPR/MAVE for clinical variant interpretation

# +RNAinsight

Paired DNA/RNA genetic testing with +RNAinsight analyzes functional RNA data to help classify DNA variants. It also identifies deep-intronic mutations that may go undetected with a DNA only or reflexive RNA testing approach. As a result, diagnostic yield is higher and variant of uncertain significance rate is lower, providing clarity for patients and healthcare providers.<sup>1</sup>This novel functional evidence is especially important in non-White populations that have been underrepresented in research and clinical testing.

# 1-90 Genes

#### For Maximum Flexibility

Order +RNAinsight with analysis of any genes on the hereditary cancer menu\*

# **5%**

#### Hereditary Cancer Cases Leverage RNA Data

RNA data can benefit all Ambry patients, even those with DNA-only testing<sup>1</sup>

# 1/25

#### Positive Patients Would Be Missed Without RNA

Results without +RNAinsight would be negative or inconclusive<sup>2</sup>

# ~6%

### **Reduction in VUS Rate**

+RNAinsight reduces ambiguity for providers and patients\*\*

# 12,000 Non-White Patients Have Benefited

+RNAinsight provided functional data to address known data gaps\*\*


Technical Details +RNAinsight analyzes transcripts for up to 90 genes depending on which Ambry Genetics DNA based Hereditary Cancer Panel it is paired with, and depending on the absence or presence of RNA transcripts expressed in the blood. The results from +RNAinsight are used to provide functional RNA information to further support classification of DNA variants. It is not intended to be used as a stand-alone diagnostic test.

	BRCANext® 19-26 Genes^	ColoNext® 20-26 genes^	CancerNext® 39 genes	CancerNext- <i>Expanded®</i> 76-90 genes^	CustomNext- <i>Cancer®</i> Choose from 90 genes^
	BRIP1		BRIP1	BRIP1	BRIP1
ATM	ATM		ATM	ATM	ATM
BARD1	BARD1		BARD1	BARD1	BARD1
BRCA1	BRCA1		BRCA1	BRCA1	BRCA1
BRCA2	BRCA2		BRCA2	BRCA2	BRCA2
CHEK2	CHEK2		CHEK2	CHEK2	CHEK2
NF1	NF1		NF1	NF1	NF1
PALB2	PALB2		PALB2	PALB2	PALB2
RAD51C	RAD51C		RAD51C	RAD51C	RAD51C
RAD51D	RAD51D		RAD51D	RAD51D	RAD51D
CDH1	CDH1	CDH1	CDH1	CDH1	CDH1
PTEN	PTEN	PTEN	PTEN	PTEN	PTEN
STK11	STK11	STK11	STK11	STK11	STK11
TP53	TP53	TP53	TP53	TP53	TP53
	MLH1	MLH1	MLH1	MLH1	MLH1
	MSH2	MSH2	MSH2	MSH2	MSH2
	MSH6	MSH6	MSH6	MSH6	MSH6
	PMS2	PMS2	PMS2	PMS2	PMS2
	EPCAM	EPCAM	EPCAM	EPCAM	EPCAM
		APC	APC	APC	APC
		AXIN2	AXIN2	AXIN2	AXIN2
		BMPR1A	BMPR1A	BMPR1A	BMPR1A
		SMAD4	SMAD4	SMAD4	SMAD4
		GREM1	GREM1	GREM1	GREM1
		MBD4	MBD4	MBD4	MBD4
		MSH3	MSH3	MSH3	MSH3
		MUTYH	MUTYH	MUTYH	MUTYH
		NTHL1	NTHL1	NTHL1	NTHL1
		POLD1	POLD1	POLD1	POLD1
		POLE	POLE	POLE	POLE
			BAP1	BAP1	BAP1
			CDKN2A	CDKN2A	CDKN2A
			FH	FH	FH
			FLCN	FLCN	FLCN
			HOXB13	HOXB13	HOXB13
			MET	MET	MET
			TSC1	TSC1	TSC1
			TSC2	TSC2	TSC2
				TSC2 VHL	TSC2 VHL
			TSC2	TSC2 VHL AIP	TSC2 VHL AIP
			TSC2	TSC2 VHL AIP ALK	TSC2 VHL AIP ALK
Add-on Options			TSC2	TSC2 VHL AIP ALK CDC73	TSC2 VHL AIP ALK CDC73
CANext (19-gene base par			TSC2	TSC2 VHL AIP ALK CDC73 CDK4	TSC2 VHL AIP ALK CDC73 CDK4
CANext (19-gene base par	nel) ATRIP, CDC73, FH, NTHL1, POLI	D1, POLE, RAD51B	TSC2	TSC2 VHL AIP ALK CDC73 CDK4 CDKN1B	TSC2 VHL AIP ALK CDC73 CDK4 CDKN1B
CANext (19-gene base par nited Evidence Genes (7): A IoNext (20-gene base pare	ATRIP, CDC73, FH, NTHL1, POLI		TSC2	TSC2 VHL AIP ALK CDC73 CDK4 CDKN1B CEPBA	TSC2 VHL AIP ALK CDC73 CDK4 CDKN1B CEPBA
CANext (19-gene base par nited Evidence Genes (7): A IoNext (20-gene base pare	ATRIP, CDC73, FH, NTHL1, POL		TSC2	TSC2 VHL AIP ALK CDC73 CDK4 CDKN1B CEPBA CTNNA1	TSC2 VHL AIP ALK CDC73 CDK4 CDKN1B CEPBA CTNNA1
CANext (19-gene base par nited Evidence Genes (7): A loNext (20-gene base pane nited Evidence Genes (6): A	ATRIP, CDC73, FH, NTHL1, POLI el) ATM, CHEK2, CTNNA1, MLH3, R		TSC2	TSC2 VHL AIP ALK CDC73 CDK4 CDKN1B CEPBA CTNNA1 DDX41	TSC2 VHL AIP ALK CDC73 CDK4 CDKN1B CEPBA CTNNA1 DDX41
CANext (19-gene base par nited Evidence Genes (7): A loNext (20-gene base pane nited Evidence Genes (6): A ncerNext-Expanded (76-gen nited Evidence Genes (9): A	ATRIP, CDC73, FH, NTHL1, POLI el) ATM, CHEK2, CTNNA1, MLH3, R	RNF43, RPS20	TSC2	TSC2VHLAIPALKCDC73CDK4CDKN1BCEPBACTNNA1DDX41DICER1	TSC2 VHL AIP ALK CDC73 CDK4 CDKN1B CEPBA CTNNA1 DDX41 DICER1
CANext (19-gene base par nited Evidence Genes (7): A loNext (20-gene base pane nited Evidence Genes (6): A ncerNext-Expanded (76-gen nited Evidence Genes (9): A IF43, RPS20, TERT	ATRIP, CDC73, FH, NTHL1, POLI el) ATM, CHEK2, CTNNA1, MLH3, Fi ene base panel)	RNF43, RPS20	TSC2	TSC2VHLAIPALKCDC73CDK4CDKN1BCEPBACTNNA1DDX41DICER1EGFR	TSC2 VHL AIP ALK CDC73 CDK4 CDKN1B CEPBA CTNNA1 DDX41 DICER1 EGFR
CANext (19-gene base par hited Evidence Genes (7): A loNext (20-gene base pane hited Evidence Genes (6): A ncerNext-Expanded (76-gen hited Evidence Genes (9): A IF43, RPS20, TERT ncreatitis Genes (5): CFTR,	ATRIP, CDC73, FH, NTHL1, POLI el) ATM, CHEK2, CTNNA1, MLH3, R ene base panel) ATRIP, EGLN1, KIF1B, MLH3, PA CPA1, CTRC, PRSS1, SPINK1	RNF43, RPS20	TSC2	TSC2 VHL AIP ALK CDC73 CDK4 CDKN1B CCPBA CTNNA1 DDX41 DDX41 DICER1 EGFR ETV6	TSC2 VHL AIP ALK CDC73 CDK4 CDKN1B CEPBA CTNNA1 DDX41 DICER1 EGFR ETV6
CANext (19-gene base par nited Evidence Genes (7): A loNext (20-gene base pare nited Evidence Genes (6): A ncerNext-Expanded (76-gen nited Evidence Genes (9): A IF43, RPS20, TERT ncreatitis Genes (5): CFTR, nited evidence gene available a	ATRIP, CDC73, FH, NTHL1, POLI el) ATM, CHEK2, CTNNA1, MLH3, R ene base panel) ATRIP, EGLN1, KIF1B, MLH3, PA	SNF43, RPS20	TSC2	TSC2VHLAIPALKCDC73CDK4CDKN1BCEPBACTNNA1DDX41DICER1EGFRETV6GATA2	TSC2VHLAIPALKCDC73CDK4CDKN1BCEPBACTNNA1DDX41DICER1EGFRETV6GATA2
CANext (19-gene base par nited Evidence Genes (7): A loNext (20-gene base pare nited Evidence Genes (6): A ncerNext-Expanded (76-gen nited Evidence Genes (9): A IF43, RPS20, TERT ncreatitis Genes (5): CFTR, nited evidence gene available a	ATRIP, CDC73, FH, NTHL1, POLI el) ATM, CHEK2, CTNNA1, MLH3, R ene base panel) ATRIP, EGLN1, KIF1B, MLH3, PA , CPA1, CTRC, PRSS1, SPINK1 s part of an add-on selection to a tes	SNF43, RPS20	TSC2	TSC2VHLAIPALKCDC73CDK4CDKN1BCEPBACTNNA1DDX41DICER1EGFRETV6GATA2KIT	TSC2VHLAIPALKCDC73CDK4CDKN1BCEPBACTNNA1DDX41DICER1EGFRETV6GATA2KIT
CANext (19-gene base par nited Evidence Genes (7): A loNext (20-gene base pare nited Evidence Genes (6): A ncerNext-Expanded (76-gen nited Evidence Genes (9): A IF43, RPS20, TERT ncreatitis Genes (5): CFTR, nited evidence gene available a	ATRIP, CDC73, FH, NTHL1, POLI el) ATM, CHEK2, CTNNA1, MLH3, R ene base panel) ATRIP, EGLN1, KIF1B, MLH3, PA , CPA1, CTRC, PRSS1, SPINK1 s part of an add-on selection to a tes	SNF43, RPS20	TSC2	TSC2   VHL   AIP   ALK   CDC73   CDK4   CDKN1B   CCPBA   CTNNA1   DDX41   DICER1   EGFR   ETV6   GATA2   KIT   LZTR1	TSC2VHLAIPALKCDC73CDK4CDKN1BCEPBACTNNA1DDX41DICER1EGFRETV6GATA2KITLZTR1
CANext (19-gene base par hited Evidence Genes (7): A loNext (20-gene base pane hited Evidence Genes (6): A ncerNext-Expanded (76-gun hited Evidence Genes (9): A IF43, RPS20, TERT increatitis Genes (5): CFTR, hited evidence gene available a dence to support a causal role Additional CustomNext	ATRIP, CDC73, FH, NTHL1, POLI el) ATM, CHEK2, CTNNA1, MLH3, R ene base panel) ATRIP, EGLN1, KIF1B, MLH3, PA , CPA1, CTRC, PRSS1, SPINK1 s part of an add-on selection to a test for this gene in association with cance -Cancer Genes	RNF43, RPS20	TSC2	TSC2   VHL   AIP   ALK   CDC73   CDK4   CDKN1B   CEPBA   CTNNA1   DDX41   DICER1   EGFR   GATA2   KIT   LZTR1   MAX	TSC2VHLAIPALKCDC73CDK4CDKN1BCEPBACTNNA1DDX41DICER1EGFREGFRETV6GATA2KITLZTR1MAX
CANext (19-gene base par hited Evidence Genes (7): A loNext (20-gene base pane hited Evidence Genes (6): A ncerNext-Expanded (76-gen hited Evidence Genes (9): A IF43, RPS20, TERT increatitis Genes (5): CFTR, hited evidence gene available a dence to support a causal role Additional CustomNext hited Evidence Genes (Cho	ATRIP, CDC73, FH, NTHL1, POLI al) ATM, CHEK2, CTNNA1, MLH3, R ene base panel) ATRIP, EGLN1, KIF1B, MLH3, PA , CPA1, CTRC, PRSS1, SPINK1 s part of an add-on selection to a test for this gene in association with cance <b>-Cancer Genes</b> ose from 9): ATRIP, EGLN1, KIF	RNF43, RPS20	TSC2	TSC2   VHL   AIP   ALK   CDC73   CDK4   CDKN1B   CCPBA   CTNNA1   DDX41   DICER1   EGFR   GATA2   KIT   LZTR1   MAX   MEN1	TSC2   VHL   AIP   ALK   CDC73   CDK4   CDKN1B   CEPBA   CTNNA1   DDX41   DICER1   EGFR   ETV6   GATA2   KIT   LZTR1   MAX   MEN1
CANext (19-gene base par hited Evidence Genes (7): A loNext (20-gene base pane hited Evidence Genes (6): A ncerNext-Expanded (76-gen hited Evidence Genes (9): A F43, RPS20, TERT increatitis Genes (5): CFTR, ited evidence gene available a dence to support a causal role Additional CustomNext hited Evidence Genes (Cho LLD, RAD51B, RNF43, RP	ATRIP, CDC73, FH, NTHL1, POLI al) ATM, CHEK2, CTNNA1, MLH3, R ene base panel) ATRIP, EGLN1, KIF1B, MLH3, PA , CPA1, CTRC, PRSS1, SPINK1 s part of an add-on selection to a test for this gene in association with cance <b>-Cancer Genes</b> ose from 9): ATRIP, EGLN1, KIF	IB, MLH3,	TSC2	TSC2   VHL   AIP   ALK   CDC73   CDK4   CDKN1B   CCPBA   CTNNA1   DDX41   DICER1   EGFR   EGFR   KIT   LZTR1   MAX   MEN1   MITF	TSC2   VHL   AIP   ALK   CDC73   CDK4   CDKN1B   CEPBA   CTNNA1   DDX41   DICER1   EGFR   ETV6   GATA2   KIT   LZTR1   MAX   MEN1   MITF
CANext (19-gene base par ited Evidence Genes (7): A oNext (20-gene base pane ited Evidence Genes (6): A ncerNext-Expanded (76-genited Evidence Genes (9): A F43, RPS20, TERT increatitis Genes (5): CFTR, ited evidence gene available a lence to support a causal role Additional CustomNext ited Evidence Genes (Cho LLD, RAD51B, RNF43, RP	ATRIP, CDC73, FH, NTHL1, POLI al) TM, CHEK2, CTNNA1, MLH3, R ene base panel) ATRIP, EGLN1, KIF1B, MLH3, PA , CPA1, CTRC, PRSS1, SPINK1 s part of an add-on selection to a test for this gene in association with cance <b>CCancer Genes</b> ose from 9): ATRIP, EGLN1, KIF3 S20, TERT	IB, MLH3,	TSC2	TSC2   VHL   AIP   ALK   CDC73   CDK4   CDKN1B   CCPBA   CTNNA1   DDX41   DICER1   EGFR   GATA2   KIT   MAX   MEN1   MITF   NF2	TSC2   VHL   AIP   ALK   CDC73   CDK4   CDKN1B   CEPBA   CTNNA1   DDX41   DICER1   EGFR   ETV6   GATA2   KIT   LZTR1   MAX   MEN1   MITF   NF2
CANext (19-gene base par ited Evidence Genes (7): A oNext (20-gene base pane ited Evidence Genes (6): A neerNext-Expanded (76-gene) ited Evidence Genes (9): A F43, RPS20, TERT nereatitis Genes (5): CFTR, ited evidence gene available a lence to support a causal role Additional CustomNext ited Evidence Genes (Cho LD, RAD51B, RNF43, RP	ATRIP, CDC73, FH, NTHL1, POLI al) TM, CHEK2, CTNNA1, MLH3, R ene base panel) ATRIP, EGLN1, KIF1B, MLH3, PA , CPA1, CTRC, PRSS1, SPINK1 s part of an add-on selection to a test for this gene in association with cance <b>CCancer Genes</b> ose from 9): ATRIP, EGLN1, KIF3 S20, TERT	IB, MLH3,	TSC2	TSC2   VHL   AIP   ALK   CDC73   CDK4   CDKN1B   CCPBA   CTNNA1   DDX41   DDCER1   EGFR   GATA2   KIT   LZTR1   MAX   MEN1   MITF   NF2   PDGFRA	TSC2   VHL   AIP   ALK   CDC73   CDK4   CDKN1B   CEPBA   CTNNA1   DDX41   DICER1   EGFR   ETV6   GATA2   KIT   DAX   MAX   MEN1   NF2   PDGFRA
CANext (19-gene base par nited Evidence Genes (7): A oNext (20-gene base pane nited Evidence Genes (6): A ncerNext-Expanded (76-gene) nited Evidence Genes (9): A F43, RPS20, TERT ncreatitis Genes (5): CFTR, ited evidence gene available a lence to support a causal role Additional CustomNext nited Evidence Genes (Cho LD, RAD51B, RNF43, RP ncreatitis Genes (Choose fin NAinsight can be addec	ATRIP, CDC73, FH, NTHL1, POLI (a) ATM, CHEK2, CTNNA1, MLH3, R (a) (a) (b) (c) (c) (c) (c) (c) (c) (c) (c	IB, MLH3, SS1, SPINK1	TSC2	TSC2   VHL   AIP   ALK   CDC73   CDK4   CDKN1B   CCPBA   CTNNA1   DDX41   DDX41   CEFBA   KIT   ALK   MAX   MEN1   MITF   NF2   PDGFRA   PHOX2B	TSC2   VHL   AIP   ALK   CDC73   CDK4   CDK4   CDK4   CDKA   DCFBA   CTNNA1   DDX41   DICER1   EGFR   ETV6   GATA2   KIT   LZTR1   MAX   MEN1   MITF   NF2   PDGFRA   PHOX2B
CANext (19-gene base para ited Evidence Genes (7): A oNext (20-gene base para ited Evidence Genes (6): A neerNext-Expanded (76-gu ited Evidence Genes (9): A F43, RPS20, TERT increatitis Genes (5): CFTR, ited evidence gene available a lence to support a causal role Additional CustomNext ited Evidence Genes (Cho LD, RAD51B, RNF43, RP increatitis Genes (Choose fin MAinsight can be addec	ATRIP, CDC73, FH, NTHL1, POLI (a) ATM, CHEK2, CTNNA1, MLH3, R (a) (a) (b) (c) (c) (c) (c) (c) (c) (c) (c	IB, MLH3, SS1, SPINK1	TSC2	TSC2   VHL   AIP   ALK   CDC73   CDK4   CDKN1B   CCPBA   CTNNA1   DDX41   DDCER1   EGFR   GATA2   KIT   LZTR1   MAX   MITF   NF2   PDGFRA   PHOX2B   POT1	TSC2   VHL   AIP   ALK   CDC73   CDK4   CDKA   DDX41   DDX41   DDX41   DICER1   EGFR   EGFR   KIT   LZTR1   MAX   MEN1   MITF   NF2   PDGFRA   PHOX2B   POT1
CANext (19-gene base par nited Evidence Genes (7): A oNext (20-gene base pane nited Evidence Genes (6): A ncerNext-Expanded (76-gene) nited Evidence Genes (9): A F43, RPS20, TERT ncreatitis Genes (5): CFTR, ited evidence gene available a lence to support a causal role Additional CustomNext nited Evidence Genes (Cho LD, RAD51B, RNF43, RP ncreatitis Genes (Choose fin NAinsight can be addec	ATRIP, CDC73, FH, NTHL1, POLI (a) ATM, CHEK2, CTNNA1, MLH3, R (a) (a) (b) (c) (c) (c) (c) (c) (c) (c) (c	IB, MLH3, SS1, SPINK1	TSC2	TSC2   VHL   AIP   ALK   CDC73   CDK4   CDKN1B   CCPBA   CCTNNA1   DDX41   DDCER1   EGFR   GATA2   KIT   ALX   MAX   MEN1   MITF   NF2   PDGFRA   POT1   PRKAR1A	TSC2   VHL   AIP   ALK   CDC73   CDK4   CDK4   CDKA   DDX41   DDX41   DDX41   DDX41   DICER1   EGFR   EGFR   KIT   LZTR1   MAX   MEN1   MITF   NF2   PDGFRA   PHOX2B   POT1   PRKAR1A
CANext (19-gene base par nited Evidence Genes (7): A oNext (20-gene base pane nited Evidence Genes (6): A ncerNext-Expanded (76-gene) nited Evidence Genes (9): A F43, RPS20, TERT ncreatitis Genes (5): CFTR, ited evidence gene available a lence to support a causal role Additional CustomNext nited Evidence Genes (Cho LD, RAD51B, RNF43, RP ncreatitis Genes (Choose fin NAinsight can be addec	ATRIP, CDC73, FH, NTHL1, POLI (a) ATM, CHEK2, CTNNA1, MLH3, R (a) (a) (b) (c) (c) (c) (c) (c) (c) (c) (c	IB, MLH3, SS1, SPINK1	TSC2	TSC2   VHL   AIP   ALK   CDC73   CDK4   CDKN1B   CCPBA   CTNNA1   DDX41   DDCER1   EGFR   GATA2   KIT   LZTR1   MAX   MITF   MITF   PDGFRA   PHOX2B   POT1   PRKAR1A   PTCH1	TSC2   VHL   AIP   ALK   CDC73   CDK4   CDKA   DCDKA   CDX41   DDX41   DDX41   DDX41   DICER1   EGFR   EJ   CTNNA1   DICER1   EGFR   I   MAX   MAX   MEN1   MITF   NF2   PDGFRA   PHOX2B   POT1   PRKAR1A   PTCH1
CANext (19-gene base par nited Evidence Genes (7): A oNext (20-gene base pane nited Evidence Genes (6): A ncerNext-Expanded (76-gene) nited Evidence Genes (9): A F43, RPS20, TERT ncreatitis Genes (5): CFTR, ited evidence gene available a lence to support a causal role Additional CustomNext nited Evidence Genes (Cho LD, RAD51B, RNF43, RP ncreatitis Genes (Choose fin NAinsight can be addec	ATRIP, CDC73, FH, NTHL1, POLI (a) ATM, CHEK2, CTNNA1, MLH3, R (a) (a) (b) (c) (c) (c) (c) (c) (c) (c) (c	IB, MLH3, SS1, SPINK1	TSC2	TSC2   VHL   AIP   ALK   CDC73   CDK4   CDKN1B   CCPBA   CCTNNA1   DDX41   DDX41   DDCER1   EGFR   GATA2   KIT   ALX   MAX   MEN1   MITF   NF2   PDGFRA   PHOX2B   POT1   PRKAR1A   PTCH1   RB1	TSC2   VHL   AIP   ALK   CDC73   CDK4   CDKN1B   CCFPBA   CCFNNA1   DDX41   DDX41   DDCER1   EGFR   ETV6   GATA2   KIT   LZTR1   MAX   MEN1   MITF   NF2   PDGFRA   PHOX2B   POT1   PRKAR1A   PTCH1   RB1
CANext (19-gene base par nited Evidence Genes (7): A loNext (20-gene base pane nited Evidence Genes (6): A ncerNext-Expanded (76-gen nited Evidence Genes (9): A F43, RPS20, TERT ncreatitis Genes (5): CFTR, ited evidence gene available a dence to support a causal role Additional CustomNext nited Evidence Genes (Cho LLD, RAD51B, RNF43, RP ncreatitis Genes (Choose fin NAinsight can be addec	ATRIP, CDC73, FH, NTHL1, POLI (a) ATM, CHEK2, CTNNA1, MLH3, R (a) (a) (b) (c) (c) (c) (c) (c) (c) (c) (c	IB, MLH3, SS1, SPINK1	TSC2	TSC2   VHL   AIP   ALK   CDC73   CDK4   CDKN1B   CCPBA   CTNNA1   DDX41   DDCER1   EGFR   GATA2   KIT   LZTR1   MAX   MEN1   MITF   PDGFRA   PHOX2B   POT1   PRKAR1A   PTCH1   RB1   RET	TSC2   VHL   AIP   ALK   CDC73   CDK4   CDKN1B   CDKA   CCFBA   CCTNNA1   DDX41   DDX41   DICER1   EGFR   ETV6   GATA2   KIT   LZTR1   MAX   MEN1   MF2   PDGFRA   PHOX2B   POT1   PRKAR1A   PTCH1   RB1   RET
CANext (19-gene base par nited Evidence Genes (7): A loNext (20-gene base pane nited Evidence Genes (6): A ncerNext-Expanded (76-gen nited Evidence Genes (9): A F43, RPS20, TERT ncreatitis Genes (5): CFTR, ited evidence gene available a dence to support a causal role Additional CustomNext nited Evidence Genes (Cho LLD, RAD51B, RNF43, RP ncreatitis Genes (Choose fin NAinsight can be addec	ATRIP, CDC73, FH, NTHL1, POLI (a) ATM, CHEK2, CTNNA1, MLH3, R (a) (a) (b) (c) (c) (c) (c) (c) (c) (c) (c	IB, MLH3, SS1, SPINK1	TSC2	Image: Properties of the section of	TSC2   VHL   AIP   ALK   CDC73   CDK4   CDKA   DCEPBA   CTNNA1   DDX41   DDX41   DICER1   EGFR   GATA2   KIT   LZTR1   MAX   MEN1   MAX   PDGFRA   PDT1   PRKAR1A   PTCH1   RB1   RET   RUNX1
CANext (19-gene base par nited Evidence Genes (7): A loNext (20-gene base pane nited Evidence Genes (6): A ncerNext-Expanded (76-gen nited Evidence Genes (9): A F43, RPS20, TERT ncreatitis Genes (5): CFTR, ited evidence gene available a dence to support a causal role Additional CustomNext nited Evidence Genes (Cho LLD, RAD51B, RNF43, RP ncreatitis Genes (Choose fin NAinsight can be addec	ATRIP, CDC73, FH, NTHL1, POLI (a) ATM, CHEK2, CTNNA1, MLH3, R (a) (a) (b) (c) (c) (c) (c) (c) (c) (c) (c	IB, MLH3, SS1, SPINK1	TSC2	TSC2   VHL   AIP   ALK   CDC73   CDK4   CDKN1B   CCPBA   CCTNNA1   DDX41   DDCER1   EGFR   GATA2   KIT   LZTR1   MAX   MEN1   MITF   PDGFRA   PDGFRA   PDT1   PRKAR1A   RB1   RUNX1   SDHA	TSC2   VHL   AIP   ALK   CDC73   CDK4   CDKA   DDX41   DDX41   DDX41   DDX41   DDX41   DDX41   DCER1   EGFR   FTV6   GATA2   KIT   LZTR1   MAX   MEN1   MAX   PDGFRA   PDDGFRA   POT1   PRKAR1A   PTCH1   RB1   RET   RUNX1   SDHA
CANext (19-gene base par nited Evidence Genes (7): A loNext (20-gene base pane nited Evidence Genes (6): A ncerNext-Expanded (76-gen nited Evidence Genes (9): A F43, RPS20, TERT ncreatitis Genes (5): CFTR, nited evidence gene available a dence to support a causal role Additional CustomNext nited Evidence Genes (Cho LLD, RAD51B, RNF43, RP ncreatitis Genes (Choose fin NAinsight can be addec	ATRIP, CDC73, FH, NTHL1, POLI (a) ATM, CHEK2, CTNNA1, MLH3, R (a) (a) (b) (c) (c) (c) (c) (c) (c) (c) (c	IB, MLH3, SS1, SPINK1	TSC2	Image: Normal Stress (Normal Stress (Normat Stress (Normal Stress (Normal Stress (Normal Stress	TSC2   VHL   AIP   ALK   CDC73   CDK4   CDKA   DDX41   DDX41   DDX41   DICER1   EGFR   GATA2   KIT   LZTR1   MAX   MEN1   MAX   PDGFRA   PDGFRA   POT1   PRKAR1A   PTCH1   RB1   RET   SDHA   SDHB
CANext (19-gene base par hited Evidence Genes (7): A IoNext (20-gene base pane hited Evidence Genes (6): A ncerNext-Expanded (76-gene) hited Evidence Genes (9): A IF43, RPS20, TERT ncreatitis Genes (5): CFTR, hited evidence gene available a dence to support a causal role Additional CustomNext hited Evidence Genes (Cho LLD, RAD51B, RNF43, RP ncreatitis Genes (Choose fingenes) RNAinsight can be addec	ATRIP, CDC73, FH, NTHL1, POLI (a) ATM, CHEK2, CTNNA1, MLH3, R (a) (a) (b) (c) (c) (c) (c) (c) (c) (c) (c	IB, MLH3, SS1, SPINK1	TSC2	Image: Note of the section of the s	TSC2   VHL   AIP   ALK   CDC73   CDK4   CDK4   CDKA   CDKA   CDKA   DDX41   DDX41   DDX41   DDX41   CEPBA   CTNNA1   DCER1   EGFR   FTV6   GATA2   KIT   AKT   MAX   MAX   MEN1   MAX   PDGFRA   PDDGFRA   POT1   PRKAR1A   PTCH1   RB1   RET   RUNX1   SDHB   SDHB
CANext (19-gene base par hited Evidence Genes (7): A IoNext (20-gene base pane hited Evidence Genes (6): A ncerNext-Expanded (76-gene) hited Evidence Genes (9): A IF43, RPS20, TERT ncreatitis Genes (5): CFTR, hited evidence gene available a dence to support a causal role Additional CustomNext hited Evidence Genes (Cho LLD, RAD51B, RNF43, RP ncreatitis Genes (Choose fingenes) RNAinsight can be addec	ATRIP, CDC73, FH, NTHL1, POLI (a) ATM, CHEK2, CTNNA1, MLH3, R (a) (a) (b) (c) (c) (c) (c) (c) (c) (c) (c	IB, MLH3, SS1, SPINK1	TSC2	Image: Note of the section of the s	TSC2   VHL   AIP   ALK   CDC73   CDK4   CDKA   DDX41   DDX41   DDX41   DDX41   DDX41   DCER1   EGFR   FOT   MAX   MAX   MAX   MAX   MEN1   MAX   MEN1   MAX   PDGFRA   PDQFRA   POT1   PRKAR1A   PTCH1   RB1   RET   RUNX1   SDHA   SDHD   SHDC
ACANext (19-gene base par nited Evidence Genes (7): A loNext (20-gene base pane nited Evidence Genes (6): A ncerNext-Expanded (76-gene) nited Evidence Genes (9): A IF43, RPS20, TERT ncreatitis Genes (5): CFTR, nited evidence gene available a dence to support a causal role Additional CustomNext nited Evidence Genes (Cho LLD, RAD51B, RNF43, RP, ncreatitis Genes (Choose fin RNAinsight can be addec	ATRIP, CDC73, FH, NTHL1, POLI (a) ATM, CHEK2, CTNNA1, MLH3, R (a) (a) (b) (c) (c) (c) (c) (c) (c) (c) (c	IB, MLH3, SS1, SPINK1	TSC2	Image: Note of the section of the s	TSC2   VHL   AIP   ALK   CDC73   CDK4   CDKN1B   CDK4   CDKA1   DCEPBA   CDX41   DDX41   DDCER1   EGFR   EGFR   CTNNA1   DICER1   CTNNA1   DICER1   MAX   MAX   MAX   MAX   MEN1   MAX   PDGFRA   PDTI   PARKAR1A   PTCH1   RB1   RET   RUNX1   SDHB   SDHD   SHDC   SDHAF2
CANext (19-gene base par hited Evidence Genes (7): A IoNext (20-gene base pane hited Evidence Genes (6): A ncerNext-Expanded (76-gene) hited Evidence Genes (9): A IF43, RPS20, TERT ncreatitis Genes (5): CFTR, hited evidence gene available a dence to support a causal role Additional CustomNext hited Evidence Genes (Cho LLD, RAD51B, RNF43, RP ncreatitis Genes (Choose fingenes) RNAinsight can be addec	ATRIP, CDC73, FH, NTHL1, POLI (a) ATM, CHEK2, CTNNA1, MLH3, R (a) (a) (b) (c) (c) (c) (c) (c) (c) (c) (c	IB, MLH3, SS1, SPINK1	TSC2	IIVHLAIPALKCDC73CDK4CDKN1BCCPBACTNNA1DDX41DICER1EGFRGATA2GATA2KITLZTR1MAXMEN1MITFPDGFRAPHOX2BPHOX2BPTCH1PRKAR1APTCH1RB1RETSDHASDHASDHAF2SMARCA4	TSC2   VHL   AIP   ALK   CDC73   CDK4   CDKA   DDX41   DDX41   DDX41   DICER1   EGFR   EJ   CTNNA1   DICER1   EGFR   I   MAX   PDGFRA   PHOX2B   POT1   PRKAR1A   PTCH1   RB1   RET   RUNX1   SDHA   SDHA   SDHA   SDHAF2   SMARCA4
CANext (19-gene base par nited Evidence Genes (7): A loNext (20-gene base pane nited Evidence Genes (6): A ncerNext-Expanded (76-gen nited Evidence Genes (9): A F43, RPS20, TERT ncreatitis Genes (5): CFTR, nited evidence gene available a dence to support a causal role Additional CustomNext nited Evidence Genes (Cho LLD, RAD51B, RNF43, RP ncreatitis Genes (Choose fin NAinsight can be addec	ATRIP, CDC73, FH, NTHL1, POLI (a) ATM, CHEK2, CTNNA1, MLH3, R (a) (a) (b) (c) (c) (c) (c) (c) (c) (c) (c	IB, MLH3, SS1, SPINK1	TSC2	Image: Note of the section of the s	TSC2   VHL   AIP   ALK   CDC73   CDK4   CDC73   CDK4   CDC73   CDK4   CDC73   CDK4   CDC73   CDK4   CDC73   CDK4   CDC73   DCER1   DDX41   DDX41   DCER1   EGFR   GATA2   KIT   LZTR1   MAX   MEN1   MAX   PDGFRA   PDT1   PNOX2B   POT1   PRKAR1A   PTCH1   RB1   RET   SDHB   SDHB   SDHB   SDHAF2   SMARCA4   SMARCB1
CANext (19-gene base par nited Evidence Genes (7): A loNext (20-gene base pane nited Evidence Genes (6): A ncerNext-Expanded (76-gen nited Evidence Genes (9): A F43, RPS20, TERT ncreatitis Genes (5): CFTR, ited evidence gene available a dence to support a causal role Additional CustomNext nited Evidence Genes (Cho LLD, RAD51B, RNF43, RP ncreatitis Genes (Choose fin NAinsight can be addec	ATRIP, CDC73, FH, NTHL1, POLI (a) ATM, CHEK2, CTNNA1, MLH3, R (a) (a) (b) (c) (c) (c) (c) (c) (c) (c) (c	IB, MLH3, SS1, SPINK1	TSC2	IIVHLAIPALKCDC73CDK4CDKN1BCCPBACTNNA1DDX41DICER1BARAGATA2GATA2GATA2IALZTR1AMXMITFPDGFRAPHOX2BPHOX2BPTCH1PRKAR1APTCH1RB1RETSDHASDHASDHAF2SMARCA4SMARCB1SMARCB1	TSC2   VHL   AIP   ALK   CDC73   CDK4   CDKA   DDX41   DDX41   DDX41   DICER1   EGFR   EJ   ATA2   KIT   LZTR1   MAX   MAX   MAX   PDGFRA   PDGFRA   PDOT1   PRKAR1A   PTCH1   RB1   RB1   RB1   RET   SDHA   SDHA   SDHD   SDHAF2   SMARCA4   SMARCB1
CANext (19-gene base para ited Evidence Genes (7): A oNext (20-gene base para ited Evidence Genes (6): A neerNext-Expanded (76-gu ited Evidence Genes (9): A F43, RPS20, TERT increatitis Genes (5): CFTR, ited evidence gene available a lence to support a causal role Additional CustomNext ited Evidence Genes (Cho LD, RAD51B, RNF43, RP increatitis Genes (Choose fin MAinsight can be addec	ATRIP, CDC73, FH, NTHL1, POLI (a) ATM, CHEK2, CTNNA1, MLH3, R (a) (a) (b) (c) (c) (c) (c) (c) (c) (c) (c	IB, MLH3, SS1, SPINK1	TSC2	Image: Note of the section of the s	TSC2   VHL   AIP   ALK   CDC73   CDK4   CDC73   CDK4   CDC73   CDK4   CDC73   CDK4   CDC73   CDK4   CDC73   CDK4   CDC73   DCER1   DDX41   DDX41   DCER1   EGFR   GATA2   KIT   LZTR1   MAX   MEN1   MAX   PDGFRA   PDT1   PNOX2B   POT1   PRKAR1A   PTCH1   RB1   RET   SDHB   SDHB   SDHB   SDHAF2   SMARCA4   SMARCB1

## Excellent Coverage, Personalized Support

At Ambry, we believe every patient should consistently have access to high-quality testing and the confidence to know cost will not be a barrier, regardless of their personal situation.

There is no "one-size-fits-all" in healthcare; therefore, we will consider each patient's individual cost concerns, so you don't have to.



### Patient Assistance Program

If your patient needs help with the cost of testing, they can request support through our Patient Assistance Program (PAP). The PAP considers their individual financial situation and provides personalized payment options based on need.



Have your patients call or email our Billing Support team at +1 949-900-5795 or billing@ambrygen.com with any questions.

## Let us be your trusted partner

All hereditary cancer tests utilize Ambry's Classifi™ program, a proprietary, knowledge-driven engine for gene classification, variant analysis & interpretation, and reporting. The Classifi program delivers the highest quality test results and ensures we leave no stone unturned in getting answers for you and your patients.



#### References

- Horton, C., Hoang, L., Zimmermann, H., Young, C., Grzybowski, J., Durda, K., Vuong, H., Burks, D., Cass, A., LaDuca, H., Richardson, M. E., Harrison, S., Chao, E. C., & amp; Karam, R 1. (2023) Diagnostic outcomes of concurrent DNA and RNA sequencing in individuals undergoing hereditary cancer testing. JAMA Oncology. https://doi.org/10.1001/jamaoncol.2023.5586 2. Horton C, et al. Expanding the reach of paired DNA and RNA sequencing: Results from 450,000 consecutive individuals from a hereditary cancer cohort; (Oral Presentation Session 84 -
- Strategies to Interpret Germline Variants in Cancer Predispostion Genes). Presented at the Annual Meeting of The American Society of Human Genetics, November 68, 2024, in Denver,
- CO.
- \* Not available for STAT Testing or BRCAPlus.
- \*\* Based on internal data

One Enterprise, Aliso Viejo, CA 92656 USA Toll Free +1.866.262.7943 Fax +1.949.900.5501 ambrygen.com ©2024 Ambry Genetics Corporation. All rights reserved. Ambry Genetics® is a registered trademarks of Ambry Genetics Corporation. MKT-ONCO-BRO-20027-EN v39 10.02.24